Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Mol Biol Rep ; 46(3): 3477-3485, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30847849

ABSTRACT

C3H10T1/2, a mouse mesenchymal stem cell line, is a well-known in vitro model of chondrogenesis that can be easily employed to recapitulate some of the mechanisms intervening in this process. Moreover, these cells can be used to validate the effect of candidate molecules identified by high throughput screening approaches applied to the development of targeted therapy for human disorders in which chondrogenic differentiation may be involved, as in conditions characterized by heterotopic endochondral bone formation. Chondrogenic differentiation of C3H10T1/2 cells can be monitored by applying quantitative polymerase chain reaction (qPCR), one of the most sensitive methods that allows detection of small dynamic changes in gene expression between samples obtained under different experimental conditions. In this work, we have used qPCR to monitor the expression of specific markers during chondrogenic differentiation of C3H10T1/2 cells in micromass cultures. Then we have applied the geNorm approach to identify the most stable reference genes suitable to get a robust normalization of the obtained expression data. Among 12 candidate reference genes (Ap3d1, Csnk2a2, Cdc40, Fbxw2, Fbxo38, Htatsf1, Mon2, Pak1ip1, Zfp91, 18S, ActB, GAPDH) we identified Mon2 and Ap3d1 as the most stable ones during chondrogenesis. ActB, GAPDH and 18S, the most commonly used in the literature, resulted to have an expression level too high compared to the differentiation markers (Sox9, Collagen type 2a1, Collagen type 10a1 and Collagen type 1a1), therefore are actually less recommended for these experimental conditions. In conclusion, we identified nine reference genes that can be equally used to obtain a robust normalization of the gene expression variation during the C3H10T1/2 chondrogenic differentiation.


Subject(s)
Chondrogenesis/genetics , Mesenchymal Stem Cells/cytology , Real-Time Polymerase Chain Reaction/standards , Actins/genetics , Adaptor Protein Complex 3/genetics , Adaptor Protein Complex beta Subunits/genetics , Animals , Cell Differentiation/genetics , Cell Line , Cells, Cultured , Gene Expression Profiling/methods , Gene Expression Profiling/standards , Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/genetics , Mice , Mice, Inbred C3H , Proton-Translocating ATPases/genetics , Real-Time Polymerase Chain Reaction/methods , Reference Standards , Transcriptome
2.
Int J Mol Sci ; 19(4)2018 Mar 26.
Article in English | MEDLINE | ID: mdl-29587443

ABSTRACT

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic condition characterized by progressive extra-skeletal ossification leading to cumulative and severe disability. FOP has an extremely variable and episodic course and can be induced by trauma, infections, iatrogenic harms, immunization or can occur in an unpredictable way, without any recognizable trigger. The causative gene is ACVR1, encoding the Alk-2 type I receptor for bone morphogenetic proteins (BMPs). The signaling is initiated by BMP binding to a receptor complex consisting of type I and II molecules and can proceed into the cell through two main pathways, a canonical, SMAD-dependent signaling and a p38-mediated cascade. Most FOP patients carry the recurrent R206H substitution in the receptor Glycine-Serine rich (GS) domain, whereas a few other mutations are responsible for a limited number of cases. Mutations cause a dysregulation of the downstream BMP-dependent pathway and make mutated ACVR1 responsive to a non-canonical ligand, Activin A. There is no etiologic treatment for FOP. However, many efforts are currently ongoing to find specific therapies targeting the receptor activity and the downstream aberrant pathway at different levels or targeting cellular components and/or processes that are important in modifying the local environment leading to bone neo-formation.


Subject(s)
Activin Receptors, Type I/genetics , Amino Acid Substitution , Myositis Ossificans/drug therapy , Activin Receptors, Type I/metabolism , Activins/metabolism , Bone Morphogenetic Proteins/metabolism , Clinical Trials as Topic , Drug Repositioning , Humans , Myositis Ossificans/etiology , Myositis Ossificans/genetics , Signal Transduction/drug effects
3.
Cytometry B Clin Cytom ; 94(4): 613-622, 2018 07.
Article in English | MEDLINE | ID: mdl-28985649

ABSTRACT

BACKGROUND: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by sporadic heterozygous mutations in ACVR1 gene which progressively leads to severe heterotopic ossification. FOP is characterized by episodic flare-ups triggered by different factors such as viral infections, tissue injuries, vaccinations, or occurring without a recognizable cause. The sporadic course of the disease, the documented presence of an important inflammatory reaction in early lesions and the partial response to corticosteroids support the idea that the immune system, and in particular the innate component, may play a role in FOP pathogenesis. However, an extensive expression profile of the peripheral blood mononuclear cells (PBMC) of FOP patients has never been done. METHODS: In this study, we carried out a wide PBMC immunophenotyping on a cohort of FOP patients and matching controls by multiparametric analysis of the expression of a panel of 37 markers associated with migration, adhesion, inhibition, activation, and cell death of circulating immune cells. RESULTS: We observed a statistically significant increase of the expression of DNAM1 receptor in patients' monocytes as compared to controls, and little but significant differences in the expression profile of CXCR1 (CD181), CD62L, CXCR4 (CD184), and HLA-DR molecules. CONCLUSIONS: DNAM1 had been previously shown to play a pivotal role in monocyte migration through the endothelial barrier and the increased expression detected in patients' monocytes might suggest a role of this surface receptor during the early phases of FOP flare-ups in which the activation of the immune response is believed to represent a crucial event. © 2017 International Clinical Cytometry Society.


Subject(s)
Antigens, Differentiation, T-Lymphocyte/biosynthesis , Leukocytes, Mononuclear/immunology , Myositis Ossificans/immunology , Adolescent , Adult , Child , Female , Humans , Immunophenotyping , Leukocytes, Mononuclear/metabolism , Male , Myositis Ossificans/metabolism , Up-Regulation , Young Adult
5.
Dis Model Mech ; 9(6): 685-96, 2016 06 01.
Article in English | MEDLINE | ID: mdl-27125279

ABSTRACT

The ACVR1 gene encodes a type I receptor of bone morphogenetic proteins (BMPs). Activating mutations in ACVR1 are responsible for fibrodysplasia ossificans progressiva (FOP), a rare disease characterized by congenital toe malformation and progressive heterotopic endochondral ossification leading to severe and cumulative disability. Until now, no therapy has been available to prevent soft-tissue swelling (flare-ups) that trigger the ossification process. With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. The screening, based on an ACVR1 promoter assay, was followed by an in vitro and in vivo test to validate and characterize candidate molecules. Among compounds that modulate the ACVR1 promoter activity, we selected the one showing the highest inhibitory effect, dipyridamole, a drug that is currently used as a platelet anti-aggregant. The inhibitory effect was detectable on ACVR1 gene expression, on the whole Smad-dependent BMP signaling pathway, and on chondrogenic and osteogenic differentiation processes by in vitro cellular assays. Moreover, dipyridamole reduced the process of heterotopic bone formation in vivo Our drug repositioning strategy has led to the identification of dipyridamole as a possible therapeutic tool for the treatment of FOP. Furthermore, our study has also defined a pipeline of assays that will be useful for the evaluation of other pharmacological inhibitors of heterotopic ossification.


Subject(s)
Activin Receptors, Type I/genetics , High-Throughput Screening Assays/methods , Myositis Ossificans/drug therapy , Transcription, Genetic , Animals , Biomarkers/metabolism , Bone Morphogenetic Proteins/metabolism , Calcium/metabolism , Cell Differentiation/drug effects , Cell Line , Chondrogenesis/drug effects , Dipyridamole/pharmacology , Dipyridamole/therapeutic use , Disease Models, Animal , Mice , Myositis Ossificans/metabolism , Myositis Ossificans/pathology , Ossification, Heterotopic/diagnostic imaging , Ossification, Heterotopic/pathology , Osteoblasts/cytology , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteogenesis/drug effects , Reproducibility of Results , Signal Transduction/drug effects , Smad Proteins/metabolism , Transcription, Genetic/drug effects
6.
Immunobiology ; 221(2): 291-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26547104

ABSTRACT

In a previous study, lack of IL-12 signaling in il12rb2 knock-out mice was found to predispose to lung adenocarcinoma (LAC). We asked whether specific polymorphisms of the human IL12RB2 gene may confer susceptibility to LAC. We studied IL12RB2 single nucleotide polymorphisms (SNPs) spanning from the promoter to the first untranslated exon of the gene. Genotypes of 49 individuals with LAC were compared with those of 93 healthy subjects. Two allele variants were found to be associated with increased susceptibility to LAC. One haplotype (hap), hap18, was more frequent in patients (18%) versus controls (6%) and significantly associated with increased probability of disease occurrence. Furthermore, IL-12 driven STAT4 phosphorylation in T cell blasts from healthy individuals was found to correlate with both single allele variants and haplotypes. In conclusion, genetically determined low signaling activity of IL-12R predisposes to the development of LAC.


Subject(s)
Adenocarcinoma/genetics , Genetic Predisposition to Disease , Lung Neoplasms/genetics , Polymorphism, Single Nucleotide , Receptors, Interleukin-12/genetics , Adenocarcinoma/immunology , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Adult , Alleles , Animals , Case-Control Studies , Exons , Female , Gene Expression Regulation , Gene Frequency , Haplotypes , Humans , Interleukin-12/genetics , Interleukin-12/immunology , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Male , Middle Aged , Phosphorylation , Promoter Regions, Genetic , Receptors, Interleukin-12/immunology , Risk , STAT4 Transcription Factor/genetics , STAT4 Transcription Factor/immunology , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Untranslated Regions
7.
Sci Rep ; 4: 6459, 2014 Sep 24.
Article in English | MEDLINE | ID: mdl-25248631

ABSTRACT

High-resolution microscopy techniques such as electron microscopy, scanning tunnelling microscopy and atomic force microscopy represent well-established, powerful tools for the structural characterization of adsorbed DNA molecules at the nanoscale. Notably, the analysis of DNA contours allows mapping intrinsic curvature and flexibility along the molecular backbone. This is particularly suited to address the impact of the base-pairs sequence on the local conformation of the strands and plays a pivotal role for investigations relating the inherent DNA shape and flexibility to other functional properties. Here, we introduce novel chain descriptors aimed to characterize the local intrinsic curvature and flexibility of adsorbed DNA molecules with unknown orientation. They consist of stochastic functions that couple the curvatures of two nanosized segments, symmetrically placed on the DNA contour. We show that the fine mapping of the ensemble-averaged functions along the molecular backbone generates characteristic patterns of variation that highlight all pairs of tracts with large intrinsic curvature or enhanced flexibility. We demonstrate the practical applicability of the method for DNA chains imaged by atomic force microscopy. Our approach paves the way for the label-free comparative analysis of duplexes, aimed to detect nanoscale conformational changes of physical or biological relevance in large sample numbers.


Subject(s)
DNA/analysis , DNA/chemistry , Osteopontin/chemistry , Osteopontin/genetics , DNA/genetics , Humans , Microscopy, Atomic Force , Microscopy, Electron , Nucleic Acid Conformation
8.
Orphanet J Rare Dis ; 8: 145, 2013 Sep 18.
Article in English | MEDLINE | ID: mdl-24047559

ABSTRACT

BACKGROUND: The ACVR1 gene encodes a type I receptor for bone morphogenetic proteins (BMPs). Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification in muscles and other non-skeletal tissues. Several aspects of FOP pathophysiology are still poorly understood, including mechanisms regulating ACVR1 expression. This work aimed to identify regulatory elements that control ACVR1 gene transcription. METHODS AND RESULTS: We first characterized the structure and composition of human ACVR1 gene transcripts by identifying the transcription start site, and then characterized a 2.9 kb upstream region. This region showed strong activating activity when tested by reporter gene assays in transfected cells. We identified specific elements within the 2.9 kb region that are important for transcription factor binding using deletion constructs, co-transfection experiments with plasmids expressing selected transcription factors, site-directed mutagenesis of consensus binding-site sequences, and by protein/DNA binding assays. We also characterized a GC-rich minimal promoter region containing binding sites for the Sp1 transcription factor. CONCLUSIONS: Our results showed that several transcription factors such as Egr-1, Egr-2, ZBTB7A/LRF, and Hey1, regulate the ACVR1 promoter by binding to the -762/-308 region, which is essential to confer maximal transcriptional activity. The Sp1 transcription factor acts at the most proximal promoter segment upstream of the transcription start site. We observed significant differences in different cell types suggesting tissue specificity of transcriptional regulation. These findings provide novel insights into the molecular mechanisms that regulate expression of the ACVR1 gene and that could be targets of new strategies for future therapeutic treatments.


Subject(s)
Activin Receptors, Type I/genetics , Myositis Ossificans/genetics , Promoter Regions, Genetic/genetics , Bone Morphogenetic Protein 2/genetics , Cell Line, Tumor , Computational Biology , Electrophoretic Mobility Shift Assay , HeLa Cells , Humans , Mutation , Reverse Transcriptase Polymerase Chain Reaction
9.
PLoS One ; 7(12): e50958, 2012.
Article in English | MEDLINE | ID: mdl-23227223

ABSTRACT

BACKGROUND: The ACVR1/Alk-2 gene, encoding a BMP type I receptor, is mutated in Fibrodysplasia Ossificans Progressiva, a severe form of heterotopic ossification. Regulation of ACVR1/Alk-2 expression, still poorly understood, is likely to be controlled by transcriptional and post-transcriptional mechanisms. In our work, we focused on the functional role of the 3'UTR region of the gene and on microRNAs as possible modulators of the ACVR1/Alk-2 expression. RESULTS: The ACVR1/Alk-2 3'UTR region consists of a 1.1 kb sequence harboring several putative, well-conserved binding sites for miRNAs in its proximal half, and AU-rich elements in the distal one, as assessed by bioinformatic analysis. The functional role of this region was tested in presence of transcription inhibitors and in transfection experiments in different cell lines, with a ACVR1/Alk-2-3'UTR reporter construct. By this transfection-based approach, we have also verified that three microRNAs, among those predicted to target ACVR1/Alk-2 gene by in silico analysis, can bind its 3'UTR sequence thereby modulating its expression. CONCLUSION: In this work we demonstrated that the ACVR1/Alk-2 transcript is unstable in presence of inhibitors of transcription. Functional analysis of the 3'UTR region by Luciferase reporter assays showed that it plays an inhibitory role on ACVR1/Alk-2 gene expression. Moreover, we found that specific miRNAs are involved in modulating ACVR1/Alk-2 gene expression as suggested by binding sites prediction in its 3'UTR sequence. In particular, we found that mir148b and mir365 were able to down-regulate ACVR1/Alk-2 expression, whereas mir26a showed a positive effect on its mRNA. Our data contribute to elucidate some of the mechanisms intervening in the modulation of ACVR1/Alk-2 expression. Considering that no specific and effective treatment of FOP is available, clarifying the basic mechanisms of the ACVR1/Alk-2 gene biology may provide means to develop innovative therapeutics approaches.


Subject(s)
3' Untranslated Regions/genetics , Activin Receptors, Type I/genetics , Gene Expression Regulation , Animals , Base Sequence , Binding Sites , Cell Line , Dactinomycin/pharmacology , Gene Expression Regulation/drug effects , Genes, Reporter , Humans , Mice , MicroRNAs/genetics , MicroRNAs/metabolism , Molecular Sequence Data , Mutagenesis/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism
10.
Nucleic Acids Res ; 40(11): e84, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22402493

ABSTRACT

We propose a method for the characterization of the local intrinsic curvature of adsorbed DNA molecules. It relies on a novel statistical chain descriptor, namely the ensemble averaged product of curvatures for two nanosized segments, symmetrically placed on the contour of atomic force microscopy imaged chains. We demonstrate by theoretical arguments and experimental investigation of representative samples that the fine mapping of the average product along the molecular backbone generates a characteristic pattern of variation that effectively highlights all pairs of DNA tracts with large intrinsic curvature. The centrosymmetric character of the chain descriptor enables targetting strands with unknown orientation. This overcomes a remarkable limitation of the current experimental strategies that estimate curvature maps solely from the trajectories of end-labeled molecules or palindromes. As a consequence our approach paves the way for a reliable, unbiased, label-free comparative analysis of bent duplexes, aimed to detect local conformational changes of physical or biological relevance in large sample numbers. Notably, such an assay is virtually inaccessible to the automated intrinsic curvature computation algorithms proposed so far. We foresee several challenging applications, including the validation of DNA adsorption and bending models by experiments and the discrimination of specimens for genetic screening purposes.


Subject(s)
DNA/ultrastructure , Microscopy, Atomic Force/methods , DNA/chemistry , Data Interpretation, Statistical , Humans , Nanostructures/ultrastructure , Nucleic Acid Conformation , Osteopontin/genetics , Point Mutation
11.
Pediatr Infect Dis J ; 28(2): 161-3, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19106781

ABSTRACT

An adolescent with idiopathic CD4 lymphocytopenia suffered from 4 visceral leishmaniasis relapses despite appropriate treatment. CD8 lymphocytopenia and abnormal expansion of TCRalphabeta, CD4, CD8 cells were consistently detected together with reduced export of mature T cells from thymus. This novel form of idiopathic CD4 lymphocytopenia may predispose to multiple visceral leishmaniasis relapses.


Subject(s)
Leishmaniasis, Visceral/complications , T-Lymphocytopenia, Idiopathic CD4-Positive/complications , Adolescent , Allopurinol/therapeutic use , Amphotericin B/therapeutic use , Antipruritics/therapeutic use , Female , Humans , Immunophenotyping , Keratins/metabolism , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/immunology , Lymph Nodes/pathology , Recurrence , T-Lymphocytopenia, Idiopathic CD4-Positive/immunology
12.
Pathogenetics ; 1(1): 5, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-19046415

ABSTRACT

BACKGROUND: Heterozygous mutations of MYH9, encoding the Non-Muscular Myosin Heavy Chain-IIA (NMMHC-IIA), cause a complex disorder named MYH9-related disease, characterized by a combination of different phenotypic features. At birth, patients present platelet macrocytosis, thrombocytopenia and leukocyte inclusions containing NMMHC-IIA. Moreover, later in life some of them develop the additional features of sensorineural hearing loss, cataracts and/or glomerulonephritis that sometimes leads to end stage renal failure. RESULTS: To clarify the mechanism by which the mutant NMMHC-IIA could cause phenotypic anomalies at the cellular level, we examined the effect of transfection of the full-length mutated D1424H MYH9 cDNAs. We have observed, by confocal microscopy, abnormal distribution of the protein and formation of rod-like aggregates reminiscent of the leukocyte inclusions found in patients. Co-transfection of differently labeled wild-type and mutant full-length cDNAs showed the simultaneous presence of both forms of the protein in the intracellular aggregates. CONCLUSION: These findings suggest that the NMMHC-IIA mutated in position 1424 is able to interact with the WT form in living cells, despite part of the mutant protein precipitates in non-functional aggregates. Transfection of the entire WT or mutant MYH9 in cell lines represents a powerful experimental model to investigate consequences of MYH9 mutations.

13.
J Clin Endocrinol Metab ; 93(3): 1005-12, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18160466

ABSTRACT

CONTEXT: Causal mutations have been detected only in a minority of isolated GH deficiency (IGHD) patients. Idiopathic IGHD might be the result of the interaction between several low-penetrance genetic factors and the environment. OBJECTIVE: The aim of this study was to test the contribution to IGHD of genetic variations in the GH1 gene regulatory regions. DESIGN AND PATIENTS: A case-control association study was performed including 118 sporadic IGHD patients with a nonsevere phenotype (height -4/-1 sd score and partial GH deficiency) and two control groups, normal stature (n=200) and short-stature individuals with normal GH secretion (n=113). Seven single-nucleotide polymorphisms in the GH1 promoter, one in the IVS4 region, and two in the locus control region were analyzed. RESULTS: The -57T allele within the vitamin D-responsive element showed a positive significant association when comparing patients with normal (P=0.006) or short stature (P=0.0011) controls. The genotype -57TT showed an odds ratio of 2.93 (1.44-5.99) and 2.99 (1.42-6.31), respectively. The functional relevance of the -57 variation was demonstrated by the luciferase assay in the presence of vitamin D. The vitamin D-induced inhibition of luciferase activity was significantly (P=0.012) stronger for the promoter haplotype carrying the associated variation -57T [haplotype #1 (hp#1)] with respect to hp#2, bearing -57G. Replacement of the T with a G at -57 on hp#1 abolished the repression, demonstrating that the T at position -57 is necessary to determine the greater vitamin D-induced inhibitory effect of hp#1. EMSA experiments showed a different band-shift pattern of the T and G sequences. CONCLUSION: The common -57G-->T polymorphism contributes to IGHD susceptibility, indicating that it may have a multifactorial etiology.


Subject(s)
Human Growth Hormone/deficiency , Human Growth Hormone/genetics , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Vitamin D/physiology , Case-Control Studies , Child , Child, Preschool , Electrophoretic Mobility Shift Assay , Female , Haplotypes , Humans , Male , Response Elements
14.
Mol Cell Endocrinol ; 249(1-2): 51-7, 2006 Apr 25.
Article in English | MEDLINE | ID: mdl-16517055

ABSTRACT

The proximal promoter of the human growth hormone gene (GH1) is highly polymorphic. We tested if promoter haplotypes differing at possibly functional sites, namely -278T/G (in the NF1 binding site), -75A/G (in the proximal Pit-1 binding site) and -57G/T (in the VDR binding site), induced a different luciferase activity when transfected in a rat pituitary cell line. The presence of a G instead of an A at position -75 induced a more than two-fold reduced activity (p<0.0001). In accordance with this findings the electrophoretic mobility shift assay demonstrated a reduced affinity of the -75G for the pituitary transcription factor Pit-1. Despite the strong effect of this polymorphism in vitro, the -75G variation was not associated to an impairment of the GH secretion in vivo.


Subject(s)
Gene Expression Regulation , Human Growth Hormone/genetics , Polymorphism, Genetic , Promoter Regions, Genetic , Transcription Factor Pit-1/metabolism , Animals , Binding Sites , Cell Line , Electrophoretic Mobility Shift Assay , Genes, Reporter , Haplotypes , Human Growth Hormone/metabolism , Humans , Luciferases/metabolism , Rats
15.
FEBS Lett ; 580(8): 1983-7, 2006 Apr 03.
Article in English | MEDLINE | ID: mdl-16530192

ABSTRACT

Eukaryotic initiation factor 6 (eIF6, alias p27BBP) is required for the biogenesis of 60S ribosomal subunits. eIF6 expression levels are tightly regulated in vivo, where they correlate with cellular growth. We analyzed how transcriptional regulation of eIF6 is achieved. We show that the human eIF6 promoter contains consensus sites for the GABP (GA-binding protein) transcription factor complex. Functional analysis of GABP consensus sequences by point mutations, EMSA (electrophoretic mobility shift assay) and a dominant negative mutant indicates that GABP is essential for eIF6 promoter activity. These data strengthen the hypothesis that GABP is a global regulator of ribosome synthesis.


Subject(s)
Carrier Proteins/genetics , GA-Binding Protein Transcription Factor/metabolism , Gene Expression Regulation , Intermediate Filament Proteins/genetics , Ribosomes/metabolism , Trans-Activators/genetics , Transcription, Genetic , Cell Nucleolus/metabolism , Consensus Sequence/genetics , Dimerization , Eukaryotic Initiation Factors , HeLa Cells , Humans , Promoter Regions, Genetic/genetics , Protein Binding , Sequence Deletion/genetics
16.
Eur J Hum Genet ; 13(6): 789-92, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15785774

ABSTRACT

The LMX1B gene, encoding a protein involved in limb, kidney and eye development, is mutated in patients affected by Nail-Patella syndrome. Inter- and intrafamilial variability is common in this disorder for skeletal abnormalities, presence and severity of nephropathy and ocular anomalies. Phenotypic variability might depend on interactions of the LMX1B causative gene with other genes during development of both kidney and eye, which might act as modifier genes. Results are presented on the interaction between LMX1B and PAX2 proteins, obtained by both direct yeast two-hybrid assay and coimmunoprecipitation. Such interaction provides support to further studies on pathways underlying important developmental processes.


Subject(s)
DNA-Binding Proteins/genetics , Homeodomain Proteins/genetics , Nail-Patella Syndrome/genetics , Transcription Factors/genetics , Animals , COS Cells , Chlorocebus aethiops , DNA-Binding Proteins/physiology , Homeodomain Proteins/physiology , Humans , Immunoprecipitation , LIM-Homeodomain Proteins , PAX2 Transcription Factor , Phenotype , Transcription Factors/physiology , Two-Hybrid System Techniques , Yeasts
17.
Physiol Genomics ; 20(1): 87-96, 2004 Dec 15.
Article in English | MEDLINE | ID: mdl-15479859

ABSTRACT

Understanding the molecular mechanisms that underlie regulation of transcription of the human osteopontin encoding gene (OPN) may help to clarify several processes, such as fibrotic evolution of organ damage, tumorigenesis and metastasis, and immune response, in which OPN overexpression is observed. With the aim to evaluate variants with functional effect on transcription, we have analyzed the promoter region and focused our investigation on three common variants present in the first 500 bp upstream of the transcription start site. Transfection of constructs carrying the four most frequent haplotypes relative to variants at -66, -156, and -443 fused to the luciferase reporter gene in a panel of different cell lines showed that one haplotype conferred a significantly reduced level of reporter gene expression in all tested cell lines. We describe that the -66 polymorphism modifies the binding affinity for the SP1/SP3 transcription factors, the -156 polymorphism is included in a yet uncharacterized RUNX2 binding site, and the -443 polymorphism causes differential binding of an unknown factor. The finding of differential effects of various combination of variants in haplotypes may contribute to explain data of association studies reported in several already published articles. Future association studies using haplotypes instead of single OPN variants will allow to achieve more accurate results referable to differential expression of OPN in several common diseases, in which OPN is considered a candidate susceptibility gene.


Subject(s)
Gene Expression Regulation , Polymorphism, Genetic , Promoter Regions, Genetic , Sialoglycoproteins/genetics , Transcription, Genetic , Alleles , Animals , Base Sequence , Binding Sites , COS Cells , Cell Line , Chlorocebus aethiops , Core Binding Factor Alpha 1 Subunit/metabolism , DNA Primers/chemistry , Genes, Reporter , Genetic Vectors , Haplotypes , HeLa Cells , Humans , Introns , Linkage Disequilibrium , Luciferases/metabolism , Mice , Mice, Knockout , Models, Genetic , Molecular Sequence Data , Neoplasm Metastasis , Osteopontin , Plasmids/metabolism , Polymerase Chain Reaction , Polymorphism, Single Nucleotide , Protein Binding , Sequence Homology, Nucleic Acid , Sp1 Transcription Factor/metabolism , Transfection
18.
Blood ; 103(4): 1376-82, 2004 Feb 15.
Article in English | MEDLINE | ID: mdl-14592838

ABSTRACT

The autoimmune/lymphoproliferative syndrome (ALPS) displays defective function of Fas, autoimmunities, lymphadenopathy/splenomegaly, and expansion of CD4/CD8 double-negative (DN) T cells. Dianzani autoimmune/lymphoproliferative disease (DALD) is an ALPS variant lacking DN cells. Both forms have been ascribed to inherited mutations hitting the Fas system but other factors may be involved. A pilot cDNA array analysis on a DALD patient detected overexpression of the cytokine osteopontin (OPN). This observation was confirmed by enzyme-linked immunosorbent assay (ELISA) detection of higher OPN serum levels in DALD patients (n = 25) than in controls (n = 50). Analysis of the OPN cDNA identified 4 polymorphisms forming 3 haplotypes (A, B, and C). Their overall distribution and genotypic combinations were different in patients (N = 26) and controls (N = 158) (P <.01). Subjects carrying haplotype B and/or C had an 8-fold higher risk of developing DALD than haplotype A homozygotes. Several data suggest that these haplotypes influence OPN levels: (1) in DALD families, high levels cosegregated with haplotype B or C; (2) in healthy controls, haplotype B or C carriers displayed higher levels than haplotype A homozygotes; and (3) in AB and AC heterozygotes, mRNA for haplotype B or C was more abundant than that for haplotype A. In vitro, exogenous OPN decreased activation-induced T-cell death, which suggests that high OPN levels are involved in the apoptosis defect.


Subject(s)
Autoimmune Diseases/genetics , Lymphoproliferative Disorders/genetics , Polymorphism, Genetic , Sialoglycoproteins/genetics , Adolescent , Adult , Autoimmune Diseases/immunology , Cells, Cultured , Child , Child, Preschool , Family Health , Female , Genetic Predisposition to Disease/epidemiology , Genotype , Humans , Lymphoproliferative Disorders/immunology , Male , Oligonucleotide Array Sequence Analysis , Osteopontin , Risk Factors , Sialoglycoproteins/blood , T-Lymphocytes/cytology , T-Lymphocytes/immunology
19.
Gene Expr ; 11(2): 95-104, 2003.
Article in English | MEDLINE | ID: mdl-12837040

ABSTRACT

The osteopontin (OPN) protein is found expressed at high level in several processes including fibrotic evolution of organ injuries, tumorigenesis, and immune response. The molecular mechanisms that underly overexpression, especially at the transcriptional level, have been only partially clarified. Therefore, this study was undertaken in search for additional DNA elements in the regulatory regions of the OPN gene and cognate transcription factors. Our results on the region upstream of the transcription start site confirmed that essential elements are located within the first 100 bp. Analysis of the sequence that includes the first untranslated exon and first intron revealed that it could enhance the promoter activity. Experiments of transfection of constructs containing different fragments of this sequence showed that most of the enhancer activity was confined in the terminal 30-bp tract of the first intron, although it was not functioning in a myofibroblast cell line. DNA/protein binding assays and cotransfection experiments showed that the C/EBP-beta transcription factor was able to bind a recognition sequence in this 30-bp segment. We found a bi-allelic sequence polymorphism at +245 in the first intron, which did not show a significant functional effect, but is a useful tool for future association studies.


Subject(s)
CCAAT-Enhancer-Binding Protein-beta/genetics , Enhancer Elements, Genetic , Introns/genetics , Promoter Regions, Genetic/genetics , Sialoglycoproteins/genetics , Base Sequence , Binding Sites , Cell Line , DNA/metabolism , Gene Expression Regulation , Humans , Molecular Sequence Data , Osteopontin , Phosphoproteins/genetics , Phosphoproteins/metabolism , Regulatory Sequences, Nucleic Acid , Response Elements , Sialoglycoproteins/metabolism , Transcription Initiation Site
SELECTION OF CITATIONS
SEARCH DETAIL